Tuscaloosa Research & Education Advancement Corporation (TREAC) Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Tuscaloosa United States (1991)

Organization Overview

First Clinical Trial
2001
NCT00203463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Lori Davis, MD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 4)

Dementia (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Disease (Phase 4)

Hypercholesterolemia (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Psychomotor Agitation (Phase 3)

Stress Disorders, Post-Traumatic (Phase 4)

Stress Disorders, Traumatic (Phase 4)

Substance-Related Disorders (Phase 4)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 11